New drug discovery targets relevant to neurodegenerative diseases

Informazioni relative al progetto

DRUGS IN NEURODEGENE

ID dell’accordo di sovvenzione: QLK6-CT-1999-50409

Progetto chiuso

Data di avvio 17 Aprile 2001

Data di completamento 16 Aprile 2005

Finanziato da

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Costo totale € 202 224,00

Contributo UE € 202 224,00

Coordinato da

SCHERING-PLOUGH SPA
Italy

Obiettivo

The aim of the project is to study neuroprotection in experimental models of human diseases. In particular we will study the effects of capsize inhibitors and that of cannabinoid receptor activity.

Campo scientifico

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery

Programma(i)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Argomento(i)

• 1.1.1.-6. - Key action The Ageing Population and Disabilities

Invito a presentare proposte

Data not available

Meccanismo di finanziamento

BUR - Bursaries, grants, fellowships

Coordinatore

SCHERING-PLOUGH SPA

• Contributo UE: Nessun dato
• Indirizzo: via Olgettina 58 ; 20132 MILANO ; Italia
• Costo totale: Nessun dato